COVID vaccine clinical trials doomed to fail; fatal design flaw; NY Times opinion piece exposes all three major clinical trials

0
236

by Jon Rappoport, No More Fake News:

PART ONE: THE FAILURE

Peter Doshi, associate editor of the medical journal BMJ, and Eric Topol, Scripps Research professor of molecular medicine, have written a devastating NY Times opinion piece about the ongoing COVID vaccine clinical trials.

They expose the fatal flaw in the large Pfizer, AstraZeneca, and Moderna trials.

September 22, the Times: “These Coronavirus Trials Don’t Answer the One Question We Need to Know”:

“If you were to approve a coronavirus vaccine, would you approve one that you only knew protected people only from the most mild form of Covid-19, or one that would prevent its serious complications?”

“The answer is obvious. You would want to protect against the worst cases.”

“But that’s not how the companies testing three of the leading coronavirus vaccine candidates, Moderna, Pfizer and AstraZeneca, whose U.S. trial is on hold, are approaching the problem.”

“According to the protocols for their studies, which they released late last week, a vaccine could meet the companies’ benchmark for success if it lowered the risk of mild Covid-19, but was never shown to reduce moderate or severe forms of the disease, or the risk of hospitalization, admissions to the intensive care unit or death.”

“To say a vaccine works should mean that most people no longer run the risk of getting seriously sick. That’s not what these trials will determine.”

This means these clinical trials are dead in the water.

The trials are designed to show effectiveness in preventing mild cases of COVID, which nobody should care about, because mild cases naturally run their course and cause no harm. THERE IS NO NEED FOR A VACCINE THAT PREVENTS MILD CASES.

Now let’s go deeper. Read the next section from the Times piece, and then I’ll make comments.

“The Moderna and AstraZeneca studies will involve about 30,000 participants each; Pfizer’s will have 44,000. Half the participants will receive two doses of vaccines separated by three or four weeks, and the other half will receive saltwater placebo shots. The final determination of efficacy will occur after 150 to 160 participants develop Covid-19…”

Here’s how it works. The vaccine companies are looking for a total of 150 (mild) COVID cases to occur, combined, in the two groups; those receiving the placebo and those receiving the vaccine. How would that happen? The researchers believe ‘the coronavirus is spreading everywhere and it will pounce on some of the volunteers in the clinical trial.’

Let’s say that, during the trial, 100 people receiving the placebo develop mild COVID-19, and only 50 people receiving the vaccine develop mild COVID.

The vaccine companies would say, ‘We just proved the vaccine is 50% effective in preventing COVID, and that’s all we need to do, in order to win authorization from the FDA. Release the vaccine. Inject the world.’

The irrelevant outcomes for 150 people equal ‘let’s shoot up seven billion people.’ That’s staggering.

But it gets even worse. The magic number of 150 COVID cases? How is a COVID case defined? The authors of the Times piece have the answer:

“In the Moderna and Pfizer trials, even a mild case of Covid-19 — for instance, a cough plus a positive lab test — would qualify and muddy the results. AstraZeneca is slightly more stringent but would still count mild symptoms like a cough plus fever as a case.”

But wait. The NY Times itself recently published an article stating that up to 90% of US COVID cases could very well be false positives—in other words, not cases at all. Why? Because the diagnostic PCR test, as it is performed by many labs, is too sensitive. It registers ‘positive for COVID’ when it shouldn’t.

Read More @ JonRappoport.com